Gritstone Earns 2022 Great Place to Work Certification™
02 juin 2022 08h00 HE
|
Gritstone bio
EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of GRANITE and Trial in Progress Poster at ASCO
31 mai 2022 08h00 HE
|
Gritstone bio
-- Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response as presented at ESMO 2021 will...
Gritstone to Participate in H.C. Wainwright Global Investment Conference
17 mai 2022 17h00 HE
|
Gritstone bio
EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced...
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
06 mai 2022 19h30 HE
|
Gritstone bio
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines...
Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
05 mai 2022 16h05 HE
|
Gritstone bio
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines...
Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Opportunity for Shareholders
02 mai 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27 avr. 2022 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery
12 avr. 2022 16h35 HE
|
Gritstone bio
-- Translational immunology data and cassette design capabilities enabled development of an optimized, KRAS-specific version of “off-the-shelf” vaccine candidate now in Phase 2 (SLATE-KRAS) -- --...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 mars 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate Updates
10 mars 2022 16h05 HE
|
Gritstone bio
-- Four trials now initiated for CORAL, Gritstone’s second-generation COVID-19 program focused on delivering T cell enhanced self-amplifying mRNA (samRNA) vaccines -- -- Oncology programs advancing...